CN101663312B - 大环多晶型物，包含这类多晶型物的组合物及其使用和制备方法 - Google Patents

大环多晶型物，包含这类多晶型物的组合物及其使用和制备方法 Download PDF

Info

Publication number
CN101663312B
CN101663312B CN2008800091323A CN200880009132A CN101663312B CN 101663312 B CN101663312 B CN 101663312B CN 2008800091323 A CN2008800091323 A CN 2008800091323A CN 200880009132 A CN200880009132 A CN 200880009132A CN 101663312 B CN101663312 B CN 101663312B
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutical composition
tiacumicin
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CN2008800091323A
Other languages
English (en)
Chinese (zh)
Other versions
CN101663312A (zh
Inventor
邱友宏
T·M·谢
A·罗梅罗
市川幸孝
许友恭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Optimer Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38661942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101663312(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals LLC filed Critical Optimer Pharmaceuticals LLC
Publication of CN101663312A publication Critical patent/CN101663312A/zh
Application granted granted Critical
Publication of CN101663312B publication Critical patent/CN101663312B/zh
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CN2008800091323A 2007-01-22 2008-01-22 大环多晶型物，包含这类多晶型物的组合物及其使用和制备方法 Ceased CN101663312B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88195007P 2007-01-22 2007-01-22
US60/881,950 2007-01-22
US11/831,886 US7378508B2 (en) 2007-01-22 2007-07-31 Polymorphic crystalline forms of tiacumicin B
US11/831,886 2007-07-31
PCT/US2008/000735 WO2008091554A1 (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012101288303A Division CN102746353A (zh) 2007-01-22 2008-01-22 大环多晶型物，包含这类多晶型物的组合物及其使用和制备方法

Publications (2)

Publication Number Publication Date
CN101663312A CN101663312A (zh) 2010-03-03
CN101663312B true CN101663312B (zh) 2013-10-23

Family

ID=38661942

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008800091323A Ceased CN101663312B (zh) 2007-01-22 2008-01-22 大环多晶型物，包含这类多晶型物的组合物及其使用和制备方法
CN2012101288303A Pending CN102746353A (zh) 2007-01-22 2008-01-22 大环多晶型物，包含这类多晶型物的组合物及其使用和制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012101288303A Pending CN102746353A (zh) 2007-01-22 2008-01-22 大环多晶型物，包含这类多晶型物的组合物及其使用和制备方法

Country Status (23)

Country Link
US (5) US7378508B2 (OSRAM)
EP (3) EP3412678B1 (OSRAM)
JP (2) JP5468388B2 (OSRAM)
KR (2) KR20150006082A (OSRAM)
CN (2) CN101663312B (OSRAM)
BR (1) BRPI0806878A2 (OSRAM)
CA (2) CA2676061C (OSRAM)
CY (1) CY1120358T1 (OSRAM)
DK (1) DK2125850T3 (OSRAM)
ES (2) ES2821384T3 (OSRAM)
HR (1) HRP20180912T1 (OSRAM)
HU (2) HUE039395T2 (OSRAM)
IL (2) IL199984A0 (OSRAM)
LT (1) LT2125850T (OSRAM)
MX (2) MX2009007730A (OSRAM)
NZ (2) NZ578697A (OSRAM)
PL (2) PL3412678T3 (OSRAM)
PT (2) PT3412678T (OSRAM)
RU (1) RU2478643C2 (OSRAM)
SI (1) SI2125850T1 (OSRAM)
TR (1) TR201810589T4 (OSRAM)
TW (2) TWI453015B (OSRAM)
WO (1) WO2008091554A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113978B2 (ja) * 2003-11-21 2013-01-09 味の素株式会社 グルタミン酸誘導体の有機アミン塩及びその利用
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
ES2713954T3 (es) * 2004-05-14 2019-05-24 Merck Sharp & Dohme Tratamiento de enfermedades asociadas al uso de antibióticos
US7935377B2 (en) * 2004-06-04 2011-05-03 Ajinomoto Co., Inc. Crystals of free (2R, 4R)-monatin and use thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
MX2010000465A (es) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
EP2531197B1 (en) * 2010-02-05 2017-05-17 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
WO2011146624A2 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Methods of treating recurring bacterial infection
WO2012106722A2 (en) * 2011-02-04 2012-08-09 Optimer Pharmaceuticals, Inc. Treatment of bacterial infections
US20150157653A1 (en) * 2012-03-16 2015-06-11 Optimer Pharmaceuticals, Inc. Prevention of Clostridium Difficile Infection in High Risk Patients
US8722863B2 (en) 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
WO2013170142A1 (en) 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
ZA201401683B (en) 2013-03-08 2017-06-28 Cipla Ltd Pharmaceutical compositions for rectal administration
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103275153B (zh) * 2013-06-27 2016-03-23 华北制药集团新药研究开发有限责任公司 一种非达霉素晶体的制备方法
CN104560766B (zh) 2013-10-16 2017-07-28 浙江海正药业股份有限公司 一种游动放线菌菌株及其应用
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
US9862740B2 (en) 2014-02-25 2018-01-09 Olon S.P.A. Process for preparing novel forms of tiacumicin B
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
CA2940902C (en) * 2014-03-18 2022-10-25 Xellia Pharmaceuticals Aps Polymorphs and solid states of tiacumicin b
KR20160149288A (ko) 2014-05-09 2016-12-27 아스텔라스 파마 유럽 리미티드 치료 요법 티아큐미신 화합물
US20150329582A1 (en) * 2014-05-13 2015-11-19 Jef DeBrabander Small molecule compounds selective against gram-negative bacterial infections
CN104098637B (zh) 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
JP2018519344A (ja) 2015-07-03 2018-07-19 アステラス ファーマ ユーロープ リミテッド チアクマイシン化合物の新規の投薬レジメン
CN112190589A (zh) * 2020-11-17 2021-01-08 首都医科大学附属北京胸科医院 非达霉素在制备抑制鸟分枝杆菌活性的产品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
CN1688707A (zh) * 2002-07-29 2005-10-26 浩鼎生技公司 台勾霉素的制备

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4321362A (en) * 1980-06-12 1982-03-23 Eli Lilly And Company De(mycinosyloxy)tylosin and process for its production
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
DE60114865T2 (de) 2000-04-28 2006-07-27 Kosan Biosciences, Inc., Hayward Heterologe herstellung von polyketiden
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20070105791A1 (en) 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
ES2713954T3 (es) * 2004-05-14 2019-05-24 Merck Sharp & Dohme Tratamiento de enfermedades asociadas al uso de antibióticos
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
BRPI0519890A2 (pt) * 2005-01-31 2009-03-31 Optimer Pharmaceuticals Inc macrociclos de 18 elementos e seus análogos
CN101340919B (zh) 2005-10-21 2011-12-07 奥普蒂姆药物公司 治疗艰难梭菌相关的腹泻的方法
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
CN1688707A (zh) * 2002-07-29 2005-10-26 浩鼎生技公司 台勾霉素的制备

Also Published As

Publication number Publication date
IL220255A0 (en) 2012-07-31
CA2676061A1 (en) 2008-07-31
RU2478643C2 (ru) 2013-04-10
EP2468761A1 (en) 2012-06-27
US20130252914A1 (en) 2013-09-26
KR20150006082A (ko) 2015-01-15
MX348083B (es) 2017-05-25
NZ578697A (en) 2012-08-31
AU2008209580A1 (en) 2008-07-31
US20100081800A1 (en) 2010-04-01
EP2125850A1 (en) 2009-12-02
DK2125850T3 (en) 2018-07-30
US20080194497A1 (en) 2008-08-14
CN101663312A (zh) 2010-03-03
KR20090117924A (ko) 2009-11-16
US7378508B2 (en) 2008-05-27
EP3412678B1 (en) 2020-08-19
HRP20180912T1 (hr) 2018-07-27
JP2013241440A (ja) 2013-12-05
PT2125850T (pt) 2018-07-11
TWI453015B (zh) 2014-09-21
PL2125850T3 (pl) 2018-08-31
HUE039395T2 (hu) 2018-12-28
CN102746353A (zh) 2012-10-24
US8859510B2 (en) 2014-10-14
TW200840562A (en) 2008-10-16
US20090163428A1 (en) 2009-06-25
US7863249B2 (en) 2011-01-04
WO2008091554A1 (en) 2008-07-31
PL3412678T3 (pl) 2020-12-14
BRPI0806878A2 (pt) 2014-06-24
CY1120358T1 (el) 2019-07-10
EP2125850B1 (en) 2018-05-30
SI2125850T1 (en) 2018-08-31
TWI425942B (zh) 2014-02-11
HUE052444T2 (hu) 2021-05-28
LT2125850T (lt) 2018-08-10
MX2009007730A (es) 2009-08-07
TR201810589T4 (tr) 2018-08-27
ES2676308T3 (es) 2018-07-18
JP2010516681A (ja) 2010-05-20
CA2880860A1 (en) 2008-07-31
CA2676061C (en) 2016-01-19
RU2009131727A (ru) 2011-02-27
EP3412678A1 (en) 2018-12-12
JP5468388B2 (ja) 2014-04-09
PT3412678T (pt) 2020-09-29
IL199984A0 (en) 2010-04-15
US20070259949A1 (en) 2007-11-08
NZ601347A (en) 2013-11-29
US8883986B2 (en) 2014-11-11
TW201350114A (zh) 2013-12-16
JP5764168B2 (ja) 2015-08-12
ES2821384T3 (es) 2021-04-26

Similar Documents

Publication Publication Date Title
CN101663312A (zh) 大环多晶型物，包含这类多晶型物的组合物及其使用和制备方法
US8518899B2 (en) Macrocyclic polymorphs, compositions comprising such polymorphs and methods of use and manufacture thereof
AU2011255633B2 (en) Methods of treating recurring bacterial infection
AU2008209580B2 (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
AU2012244278C1 (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
HK1172627A (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
HK1134096A (en) Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof
HK1134096B (en) Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: No. 65 Hayden Avenue, Lexington, Massachusetts, United States

Patentee after: Optimer Pharmaceuticals Inc.

Address before: California, USA

Patentee before: Optimer Pharmaceuticals Inc.

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: No. 65 Hayden Avenue, Lexington, Massachusetts, United States

Patentee after: Hao Ding biotech Co.,Ltd.

Address before: No. 65 Hayden Avenue, Lexington, Massachusetts, United States

Patentee before: Optimer Pharmaceuticals Inc.

TR01 Transfer of patent right

Effective date of registration: 20151218

Address after: New jersey, USA

Patentee after: Optimer Biotechnology Inc.

Address before: No. 65 Hayden Avenue, Lexington, Massachusetts, United States

Patentee before: Hao Ding biotech Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221012

Address after: new jersey

Patentee after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Patentee before: Optimer Biotechnology Inc.

IW01 Full invalidation of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20240403

Decision number of declaring invalidation: 567365

Granted publication date: 20131023